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Death receptor (DR) ligands such as tumor necrosis factor (TNF) have been identiﬁed as fundamental mediators of liver
damage both in mouse models and in humans. While the essential site of function of DR signaling is conceivably the
hepatocyte, a systematic analysis is missing. Using mice with conditional gene ablation, we analyzed the tissue-speciﬁc
function of DR signaling in T cell–dependent (concanavalin A) and independent (lipopolysaccharide/galactosamine) hep-
atitis and in models of bacterial infection (Listeria monocytogenes, lipopolysaccharide). We report that lipopolysaccharide/
galactosamine-induced liver injury depends on hepatocyte-intrinsic TNF receptor 1 (p55, TNFR1). In contrast, we show
that T cell–induced hepatitis was independent of TNFR1 signaling in hepatocytes, T cells, or endothelial cells. Moreover,
T cell–induced hepatitis was independent of hepatocyte-intrinsic Fas-associated protein with death domain, TNF-related
apoptosis-inducing ligand receptor, or Fas signaling. Instead, concanavalin A–induced hepatitis was completely prevented
in mice with myeloid-derived cell (MDC)–speciﬁc deletion of TNFR1. Signiﬁcantly, however, mice lacking TNFR1 in
MDCs succumbed to listeria infection, although they displayed similar sensitivity toward endotoxin-induced septic shock
when compared to control mice. These results suggest that TNFR1 signaling in MDCs is a critical mediator of both the
detrimental and the protective functions of TNF in T cell–induced hepatitis and bacterial infection, respectively. Conclu-
sion: The critical site of action of DRs is completely dependent on the nature of hepatitis; the data specify MDCs as the
essential cell type of TNFR1 function in T cell–mediated hepatitis and in the response to listeria, thereby identifying the
opposing role of MDC TNFR1 in autoimmunity and bacterial infection. (HEPATOLOGY 2016; 00:000–000)
The orchestration of an efﬁcient and regu-lated immune reaction against infectionrelies on the crosstalk of inﬂammatory cells.
Proinﬂammatory and anti-inﬂammatory molecules
such as cytokines and chemokines are the key
messengers between cells of the innate and the
adaptive immune system. The perception of these
intercellular signals depends on cell surface recep-
tors; however, the functional consequences of stimu-
lation through a particular signaling molecule are
context- and cell type–dependent, and incompletely
understood.
Abbreviations: AIH, autoimmune hepatitis; ALT, alanine aminotransferase; CD, cluster of differentiation; ConA, concanavalin A; Cre, cyclization
recombination; CXCL, chemokine (C-X-C motif) ligand; DR, death receptor; EC-KO, endothelial cell–speciﬁc knockout; FADD, Fas-associated protein
with death domain; Gal, D-galactosamine; H&E, hematoxylin and eosin; IL, interleukin; LPC, liver parenchymal cell; LPS, lipopolysaccharide;
MDC, myeloid-derived cell; PBS, phosphate-buffered saline; SEM, standard error of the mean; TC-KO, T cell–speciﬁc knockout; TNF, tumor necrosis
factor; TNFR1, TNF receptor 1; TRAILR, TNF-related apoptosis-inducing ligand receptor.
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While the immune system plays a fundamental role
in protecting the host against omnipresent infectious
pathogens, abnormally functioning immune cells
directed against self-antigens were identiﬁed as the
cause of different autoimmune diseases. In humans,
liver damage and hepatitis can be caused by many fac-
tors including infections, drugs or alcohol, as well as
autoimmune disease. Autoimmune hepatitis (AIH) is
a chronic liver disease of unknown etiology. While
the pathogenesis of AIH remains incompletely under-
stood, most evidence is consistent with a central role
of autoreactive T cell function resulting in liver paren-
chymal death and chronic liver injury. Immunosup-
pressive therapy is the mainstay of treating AIH, but
although it is highly effective, it has been associated
with an increased risk for infectious complications.
Generally, death of hepatocytes and cholangiocytes
(liver parenchymal cells [LPCs]) is the cardinal fea-
ture of liver damage and hepatitis. Death receptors
(DRs) have been implicated as principal mediators of
liver injury. LPCs are thought to be particularly sus-
ceptible to DR-induced killing given the ubiquitous
expression of these receptors in the liver.(1) Tumor
necrosis factor (TNF) as the prototypical DR ligand
is a proinﬂammatory cytokine that exerts its functions
through TNF receptors 1 (p55TNFR; TNFR1) and
2 (p75TNFR; TNFR2). Stimulation of TNFR1 leads
to the assembly of a signaling complex that activates
nuclear factor jB and mitogen-activated protein
kinase pathways. The aggregation of a second com-
plex includes binding of Fas-associated protein with
death domain (FADD), which is an indispensable
adaptor protein for the recruitment and activation of
caspase-8 and the induction of apoptosis.(2) More-
over, in the liver, FADD was shown to promote both
DR-dependent and independent cell death path-
ways.(3,4) Importantly, depending on the affected cell
type and the balance of intracellular signaling path-
ways, TNF can induce death but also promote cell
survival and immune activation in response to infec-
tion.(5-8) Drugs blocking TNF have become a central
option in the treatment of inﬂammatory diseases such
as rheumatoid arthritis, inﬂammatory bowel disease,
and AIH.(9) Importantly, however, interfering with
TNF to treat autoinﬂammatory disease increases the
risk of infectious side effects, reﬂecting again the dual
role of this cytokine.
Mechanisms of liver injury are complex, and cell cul-
ture and ex vivo analysis were found insufﬁcient to
study the intricate interaction between LPCs and
immune cells, cytokines, and the cell death–inducing
machinery. Using mouse models of hepatitis and liver
failure has become a standard to discern this complex-
ity. The most widely studied mouse models of experi-
mental hepatitis are concanavalin A (ConA)–induced
and lipopolysaccharide 1 D-galactosamine (LPS/
Gal)–induced liver injury. Treatment of mice with the
plant lectin ConA induces a strong stimulation of the
immune system, leading to liver damage that was
reported to involve T cells and natural killer T cells,
thereby recapitulating important aspects of AIH.(10) In
contrast, the LPS/Gal model of liver failure is inde-
pendent of T cells.(11) TNF has been implicated in the
development of liver damage in both models.(8,12,13)
After injection of LPS/Gal, TNF was released by
Toll-like receptor 4–positive macrophages(14) and
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TNFR1-deﬁcient mice were found to be protected
against hepatitis.(8) T cell–mediated hepatitis induced
by ConA was shown to be dependent on TNF–TNFR
signaling as mice lacking TNF or TNFR1/2 were
strongly protected.(12,15) Furthermore, it was shown
for this model that TNF was released from both mac-
rophages and T cells and that elimination of TNF
from either source led to reduced levels of hepatitis.(16)
TNF expression and induction of hepatitis required c-
Jun NH2-terminal kinase in cells of the hematopoietic
compartment as mice with selective loss of c-Jun
NH2-terminal kinase 1/2 expression in hematopoietic
cells exhibited a profound defect in the development of
hepatitis.(17) From these data, it seems plausible that,
in both models, TNF is produced by immune cells
consequently directing liver injury by activation of DRs
on LPCs.
The aim of this study was to examine the cell-
speciﬁc function of the TNFR1 pathway in models of
liver injury using mouse lines with tissue-speciﬁc dele-
tion of TNFR1. We discovered that the site of the
essential function of TNFR1 is entirely dependent on
the model of hepatitis. Moreover, we show that
myeloid-derived cell (MDC)–speciﬁc TNFR1 is criti-
cal for both the deleterious effect of TNF in T cell–
mediated hepatitis and its protective role in bacterial
infection.
Materials and Methods
GENERATION AND HANDLING
OF MICE
All mice were maintained in a C57BL/6 back-
ground. Animals were bred at the animal facilities of
the University Medical Center Hamburg-Eppendorf
(Hamburg, Germany), the University of Cologne
(Cologne, Germany), and the Biomedical Sciences
Research Center “Alexander Fleming” and received
human care. All animal procedures were conducted in
accordance with European, national, and institutional
guidelines and protocols and approved by local govern-
ment authorities (animal license number 86/11, Ham-
burg, Germany, and animal license number 2280/4-7-
2011, Athens, Greece). TNFR1 (p55TNFR) ﬂoxed
mice,(18) Fas ﬂoxed and TNF-related apoptosis-induc-
ing ligand receptor (TRAILR) ﬂoxed mice crossed to
AlfpCre have been described.(3) AlfpCre expressing
mice(19) were crossed to TNFR1FL mice to create mice
with liver parenchymal (i.e., hepatocyte and cholangio-
cyte)–speciﬁc deletion. LysMCre expressing mice(20)
were crossed to TNFR1FL mice to obtain mice with
myeloid-derived cell–speciﬁc deletion of TNFR1.
Cluster of differentiation 4 (CD4)-Cre expressing
mice (B6.Cg-Tg[Cd4-cre]1Cwi/BﬂuJ; The Jackson
Laboratory) were crossed to TNFR1FL mice to receive
T cell-speciﬁc deletion of TNFR1. Cdh-5 Cre(21)
expressing mice have been crossed to TNFR1FL mice
to obtain mice with deletion of TNFR1 in endothelial
cells. The 3DRLPC-KO mouse line was obtained by
crossing male NEMOFL/y3DRFL/FL(3) with TNFRFL/
FL;AlfpCre transgenic mice to obtain NEM-
OWT3DRFL mice. 3DRFL were intercrossed for
homozygosity of the ﬂoxed DR alleles. For listeria
infection experiments, heterozygous mice (TNFR1ﬂ/
1) were mated to cytomegalovirus-Cre mice(22) to con-
stitutively delete the sequences between the loxP sites.
The newly generated knockout allele has been desig-
nated TNFR1d.
GENOTYPING
The typing protocols of the mice used in this study
have been described.(3,19,20,23)
CONA, LPS/GAL CHALLENGE
AND LISTERIA INFECTION
ConA Challenge
Age-matched male mice between 8 and 12 weeks
old were injected intravenously with 6-9 mg of ConA
(Sigma) per kilogram of body weight. Animals were
sacriﬁced 1-8 hours after ConA; blood, spleen, and
liver were collected for analysis.
LPS/Gal, ConA/Gal, and LPS
Challenge
Gal 3 HCl (0.7 mg/g body weight; Geneaxxon
Bioscience, Germany) was administered intraperitone-
ally to age-matched and sex-matched animals 15
minutes before intraperitoneal injection of LPS (0.4
mg/g body weight, Escherichia coli O111:B4; Invivo-
gen) or intravenous injection of ConA (6 mg/kg body
weight). When challenged with LPS alone, age-
matched and sex-matched mice received 20 mg/kg
body weight intraperitoneally. Mice were monitored
for survival up to 7 days. For detailed information on
dosages see Supporting Information.
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Listeria Infection
Mice were injected intraperitoneally with 104
colony-forming units of virulent Listeria monocytogenes
strain L028 (kindly provided by Geneviere Milon, Pas-
teur Institute, France) and monitored for survival. Sur-
viving animals were sacriﬁced 12 days after injection.
QUANTIFICATION OF
CHEMOKINES AND CYTOKINES
Real-Time Polymerase Chain Reaction
Isolation of total RNA and complementary DNA
synthesis were performed as described.(3) Gene-
speciﬁc Taq Man assays were performed. Messenger
RNA expression was normalized to the expression of
the housekeeping gene glyceraldehyde 3-phosphate
dehydrogenase.
Enzyme-Linked Immunosorbent Assay
The following serum cytokines were measured using
enzyme-linked immunosorbent assay kits following
the manufacturers’ instructions: TNF, interferon-c,
interleukin-4 (IL-4), IL-6, IL-10 (all BioLegend), IL-
1b, and macrophage inﬂammatory protein 2 (R&D
Systems). Serum levels of alanine aminotransferase
(ALT) were measured using standard protocols in a
Roche-Cobas Integra 400 plus analyzer.
IMMUNE CELL ISOLATION AND
FLUORESCEIN ISOTHIOCYANATE
ANALYSIS
To isolate the immune cells from the spleen and
liver, the tissues were mechanically dissociated in 1 3
phosphate-buffered saline (PBS) 1% fetal calf serum
using a syringe plunger, passed through a 70-lm cell
strainer, and centrifuged at 390g for 10 minutes. Liver
immune cells were separated from hepatocytes by Per-
coll gradient centrifugation at 450g for 20 minutes.
Erythrocytes were lysed in 0.15 M NH4Cl, and the
remaining cells were washed and resuspended in 1 3
PBS 1% fetal calf serum. The cells were preincubated
with rat antimouse CD16/CD32 (Mouse TruStain
fcX) antibody for 10 minutes and then incubated with
40,6-diamidino-2-phenylindole, CD45 (clone 30-
F11), CD11c (clone M1/70), F4/80 (clone BM8),
Ly6C (clone HK1.4), GR-1 (clone RB6-8C5), CD3
(clone 17A2), CD8 (clone 53-6.7), CD4 (clone RM4-
5), and NK1.1 (clone PK136) antibodies (all BioLe-
gend) for 20 minutes in the dark. After two washes,
the cells were resuspended in 1 3 PBS 1% fetal calf
serum and analyzed using a BD LSR Fortessa (BD
Biosciences, San Jose, CA); the data were analyzed
using FlowJo_V10.
ANALYSIS OF LIVERS AND
IMMUNOHISTOCHEMISTRY
Histology was determined using 3-lm-thick sec-
tions of formalin-ﬁxed, parafﬁn-embedded liver tissues
stained with hematoxylin and eosin (H&E). Immuno-
histochemical staining of sections was performed as
described.(3) Antibodies used were antimouse Ly6G
(clone 1A8; BioXCell) and antimouse F4/80 (clone
A3-1; Abcam). Secondary antibodies used were goat
antirat peroxidase–conjugated (Dianova) and rabbit
antirat immunoglobulin horseradish peroxidase–
conjugated (Dako). Protein block and a diaminobenzi-
dine substrate chromogen system (Dako; K3466) were
used in all stainings.
STATISTICS
The statistical signiﬁcance of differences was deter-
mined by the Student t test using the program Prism
(GraphPad Software, Inc.). Graphs show medians 6
standard error of the mean (SEM) unless noted
otherwise.
SUPPLEMENTAL MATERIAL
The Supporting Information comprises six ﬁgures
including details on the generated mouse lines and
supporting data on the role of inﬂammatory cells, cyto-
kines, and oxidative stress.
Results
LIVER PARENCHYMAL TNFR1
SIGNALING IS DISPENSABLE FOR
T CELL–MEDIATED HEPATITIS
For ConA-induced hepatitis, it has been suggested
that DR ligands mediate damage by acting directly
upon the liver parenchyma.(12,24,25) Because FADD is
the main adaptor transmitting apoptotic signals by all
known DRs, we were intrigued to ﬁnd that mice lack-
ing this molecule selectively in the liver parenchyma
(FADDLPC-KO) were sensitive toward ConA: after
challenge with ConA, FADDLPC-KO mice showed
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similar levels of serum ALT and damaged liver area
upon histological analysis as their littermate controls
(Fig. 1). In contrast and consistent with the ﬁndings of
others,(12) we conﬁrmed that mice with a complete
deletion of TNFR1 (TNFR12/2) were fully protected
against ConA-induced liver injury (Fig. 1).
Our ﬁnding that the presence of FADD in LPCs
was dispensable for ConA-induced hepatitis but that
TNFR12/2 mice were protected prompted us to con-
sider two possibilities for the role of TNF in T cell–
mediated liver injury: (1) there is an LPC-dependent
but FADD-independent role for TNFR1 or (2) a dif-
ferent cell type than the liver parenchyma is the site of
the essential function of TNFR1. To test the hypothe-
sis that TNF directly mediates liver injury by acting
upon hepatocyte-intrinsic or cholangiocyte-intrinsic
TNFR1, we generated mice lacking the receptor
speciﬁcally in the liver parenchyma (TNFR1LPC-KO;
Supporting Fig. S1). TNFR1LPC-KO mice challenged
with ConA were as sensitive toward liver injury as their
littermate controls as shown by similar serum ALT
levels and similar extent of damaged liver area (Fig.
2A). We could also not detect statistically signiﬁcant
differences in the increase of the spleen size between
TNFR1LPC-KO and control mice (Fig. 2B). Con-
versely, in the LPS/Gal model of acute liver failure, we
found TNFR1LPC-KO mice completely protected.
Whereas all control mice died within 10 hours after
challenge with LPS/Gal, TNFR1LPC-KO animals sur-
vived (Fig. 2C; Supporting Fig. S1). While we found a
disrupted liver architecture and very high serum ALT
levels already 5 hours after LPS/Gal injection in con-
trol mice, the TNFR1LPC-KO mice presented with
normal liver architecture and low serum ALT levels
even at 10 hours after LPS/Gal injection (Fig. 2D).
After LPS/Gal challenge, TNFR1LPC-KO mice failed
to display cleaved caspase-3–positive hepatocytes,
while control animals showed abundant areas of posi-
tive cells (Supporting Fig. S4). Interestingly, ConA-
injected animals failed to show cleaved caspase-3–
positive cells (Supporting Fig. S4).
Apart from TNF, also FasL and TRAIL have been
implicated in ConA-induced liver injury.(26-28)
Because ablation of FADD or TNFR1 selectively in
LPCs failed to protect mice from ConA-induced hep-
atitis, we assumed that also mice with disruption of the
other DRs should not be protected against ConA-
induced liver damage. To test this hypothesis, we took
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FIG. 1. Liver parenchymal FADD is dispensable in ConA-induced hepatitis. (A) Serum ALT levels 8 hours after ConA injection of
mice with the indicated genotypes (n 5 12, 9, and 5, respectively). (B) H&E liver stainings of representative damaged area 8 hours
after ConA injection. Graph shows quantiﬁcation of damaged liver area (mean and SEM). In photographs, * indicates central vein,
bars 5 50 lm, and dashed line surrounds damaged area. *P< 0.05; ***P< 0.001.
                                                                                                                                      
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advantage of mice with a compound knockout of
the DRs TNFR1, Fas, and TRAILR speciﬁcally in
the liver parenchyma (3DRLPC-KO; Supporting Fig.
S1). As expected, 3DRLPC-KO mice exhibited simi-
lar levels of liver damage as their ﬂoxed littermates
after challenge with ConA (Fig. 2E). Taken
together, our results are consistent with the indis-
pensable need of FADD for the activation of pro-
caspases downstream of DR signaling. However,
after ConA challenge, as opposed to LPS/Gal-
induced hepatitis, liver injury is not mediated
through DRs of the liver parenchyma. Instead, with
these results we predicted that a different cell popu-
lation must be the site of the essential function of
TNFR1 in T cell–mediated hepatitis.
T CELL–SPECIFIC AND
ENDOTHELIAL CELL–SPECIFIC
TNFR1 IS DISPENSABLE IN
EXPERIMENTAL HEPATITIS
T cells and liver resident natural killer T cells were
shown to be of critical importance in ConA-induced
hepatitis.(10,27) Moreover, it has been demonstrated in
detailed genetic analyses that TNF was released from
both macrophages and T cells after ConA chal-
lenge.(16) Hence, we were interested to test if T cells
could also be the critical target for TNF through
TNFR1 in ConA-induced hepatitis. We therefore
generated mice with a T cell–speciﬁc knockout of
TNFR1 (TNFR1TC-KO; Supporting Fig. S1).
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FIG. 2. Liver parenchymal death receptor signaling is dispensable in ConA-induced hepatitis. (A) Serum ALT levels and quantiﬁca-
tion of damaged liver area 8 hours after ConA or PBS injection of TNFR1LPC-KO and TNFR1FL mice (n 5 14, 12, 2, and 3, respec-
tively). H&E liver stainings show representative damaged area. (B) Spleen length 8 hours after injection of ConA or PBS. (C)
Survival of TNFR1LPC-KO and TNFR1FL mice after LPS/Gal treatment (n 5 5 and 4, respectively). (D) Serum ALT levels for
TNFR1LPC-KO and TNFRFL 10 and 5 hours after LPS/Gal injection, respectively. Representative H&E staining of liver from
TNFR1LPC-KO and control mice after LPS/Gal. (E) Serum ALT levels 8 hours after ConA or PBS injection of 3DRLPC-KO and
3DRFL mice (n 5 6, 12, 3, and 2, respectively). *P < 0.05, **P < 0.01, and ***P < 0.001. In photographs, * indicates central vein,
bars 5 50 lm, and dashed line surrounds damaged area. Column graphs show mean and SEM. Abbreviation: n.t., not treated.
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TNFR1TC-KO mice showed similar sensitivity to
ConA-induced liver damage as control mice as indicated
by statistically insigniﬁcant differences in serum ALT
levels and the amount of degenerated liver area (Fig.
3A,B). Furthermore, we did not observe relevant differ-
ences in the increase of spleen size between the knockout
and the control mice after challenge with ConA (Fig.
3C). When challenged with LPS/Gal, no difference
could be detected between TNFR1TC-KO and control
mice as measured by overall survival (Fig. 3D).
Endothelial cells function as important gatekeepers
and regulators in the orchestration of inﬂammatory
responses. Moreover, within the context of ConA-
induced hepatitis it has been suggested that liver sinu-
soidal endothelial cells are critically involved in liver
injury by mediating a hypercoagulative state.(29) We
therefore asked if endothelial cells were the essential
cell type for TNFR1 function in T cell–mediated hep-
atitis. To this end we generated mice with a selective
deletion of TNFR1 in endothelial cells (Supporting
Fig. S1). TNFR1 endothelial cell–speciﬁc knockout
mice (TNFR1EC-KO) and their littermate controls dis-
played similar levels of liver damage, as measured by
serum ALT levels and damaged area quantiﬁcation on
H&E sections (Fig. 4A,B). The increase in spleen size
was also similar between TNFR1EC-KO and control
mice (Fig. 4C). Interestingly, when challenged with
LPS/Gal, no difference could be detected between
TNFR1EC-KO and control mice based on overall sur-
vival (Fig. 4D). Collectively, these data demonstrate
that LPS/Gal-mediated and T cell–mediated hepatitis
is caused independently of TNFR1 signaling in T cells
or endothelial cells.
MDCS ARE THE SITE OF
ESSENTIAL TNFR1 FUNCTION IN
T CELL–MEDIATED HEPATITIS
Macrophages and neutrophils have been demon-
strated to fulﬁll fundamental and nonredundant func-
tions in T cell–mediated liver injury.(10,30) After
injection of ConA, we found a more than 20-fold
increase in neutrophils in the livers of wild-type mice
and that circulating neutrophils in the blood doubled
in number (data not shown). To address the role of
MDC-speciﬁc TNFR1, we crossed TNFR1 ﬂoxed
mice with LysM-Cre transgenic mice to generate
TNFR1MDC-KO mice (Supporting Fig. S1). Strikingly,
upon ConA challenge, TNFR1MDC-KO mice were
completely protected against liver damage as measured
by serum ALT levels and quantiﬁcation of damaged
liver area upon histological evaluation (Fig. 5A,B).
Interestingly, however, when we measured the increase
in spleen size upon challenge with ConA we could not
ﬁnd statistically signiﬁcant differences between the
protected TNFR1MDC-KO mice and the control mice
(Fig. 5C).
ConA-mediated liver damage has been linked to the
function of different cytokines and chemokines. We
therefore analyzed their dynamics in TNFR1MDC-KO
compared to control mice (Fig. 5D-F). Remarkably, we
did not determine statistically signiﬁcant differences in
serum concentrations of TNF, interferon-c, or other
inﬂammatory cytokines between TNFR1MDC-KO and
control mice (Fig. 5D). For serum IL-10 concentrations
we found higher levels in TNFR1MDC-KO mice,
although this trend failed to reach statistical signiﬁcance
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FIG. 3. TNFR1 in T cells is dispensable in experimental hepatitis. (A) Serum ALT levels and (B) quantiﬁcation of damaged liver
area of TNFR1TC-KO and TNFR1FL mice 8 hours after ConA or PBS injection (n 5 15, 15, 2, and 3, respectively). H&E liver
stainings show representative damaged area. (C) Spleen length 8 hours after injection of ConA. (D) Survival of TNFR1TC-KO and
TNFR1FL mice after LPS/Gal injection (n 5 8 and 5, respectively). *P < 0.05, **P < 0.01, and ***P < 0.001. Column graphs show
mean and SEM. In photographs, * indicates central vein, bars 5 50 lm, and dashed line surrounds damaged area.
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(Fig. 5D). TNFR1MDC-KO mice had signiﬁcantly lower
expression for chemokine (C-C motif) ligand 2, as
measured by quantitative polymerase chain reaction; and
we observed a trend toward lower expression of chemo-
kine (C-X-C motif) ligand 1 (CXCL1) and CXCL9
in TNFR1MDC-KO mice (Fig. 5F). Hence, we asked if
chemoattraction of inﬂammatory cells could be affected
by ablation of TNFR1 in MDCs. However, when we
quantiﬁed the extent of neutrophil, macrophage,
and T-cell invasion into the liver we could not detect
marked changes in TNFR1MDC-KO mice (Supporting
Fig. S2).
THE SITE-SPECIFIC FUNCTION
OF TNFR1 IN EXPERIMENTAL
HEPATITIS IS CONTEXT-
DEPENDENT
Because we found that TNFR1MDC-KO mice were
protected from ConA-induced hepatitis, we were
interested in whether the MDC-speciﬁc function of
TNFR1 was also critical in LPS/Gal-induced liver
injury. TNFR1MDC-KO mice were as sensitive toward
LPS/Gal as their littermate controls (Fig. 6A). Chal-
lenge with ConA alone has been shown to cause liver
failure by inducing necrotic cell death, while in the
presence of Gal it leads to hepatocyte death both by
apoptosis and by necrosis.(31) Considering that pre-
treatment with Gal sensitized mice against LPC-
speciﬁc, TNFR1-driven liver failure when challenged
with LPS (Fig. 2C,D), we expected that challenge
with ConA in the presence of Gal(31) would render
TNFR1MDC-KO mice more susceptible to liver failure.
Indeed, upon pretreatment with Gal, TNFR1MDC-KO
mice died shortly after injection of ConA; and we
found increased serum ALT levels compared to Gal
treatment alone (Fig. 6B,C). Interestingly, in sharp
contrast to TNFR1MDC-KO and ﬂoxed control mice,
we found that mice with an LPC-selective ablation of
TNFR1 survived the ConA/Gal challenge (Fig. 6D).
In conjunction with the results presented above, these
data demonstrate that the mechanism of damage in
TNFR1-mediated liver injury majorly depends on the
competence of LPCs to induce the prosurvival
pathway.
MDC TNFR1 HAS A PROTECTIVE
FUNCTION IN BACTERIAL
INFECTION
Our results demonstrate that mice with LPC-
speciﬁc and MDC-speciﬁc deletion of TNFR1 were
protected against LPS/Gal-induced and ConA-
induced hepatitis, respectively. Interestingly, in con-
trast to this detrimental function of TNFR1, it was
recently demonstrated that TNFR in macrophages
played a fundamental role in orchestrating the defense
against E. coli in a model of urinary tract infection.(6)
Upon infection with L. monocytogenes, hepatocytes and
macrophages have been identiﬁed as critical sites for
bacterial inoculation and proliferation. As mice with
complete ablation of TNFR1 were found to succumb
to listeria infection,(8) we suspected that the sites of the
essential function of TNFR1 could be hepatocytes or
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FIG. 4. TNFR1 in endothelial cells is dispensable in experimental hepatitis. (A) Serum ALT levels and (B) quantiﬁcation of dam-
aged liver area of TNFR1EC-KO and TNFR1FL mice 8 hours after ConA or PBS injection (n 5 12, 13, 5, and 5, respectively). H&E
liver stainings show representative damaged area. (C) Spleen length 8 hours after injection of ConA. (D) Survival of TNFR1EC-KO
and TNFR1FL mice after LPS/Gal treatment (n 5 5 and 8, respectively). *P < 0.05, **P < 0.01, and ***P < 0.001. Column graphs
show mean and SEM. In photographs, * indicates central vein, bars 5 50 lm, and dashed line surrounds damaged area.
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FIG. 5. MDCs are the site of essential TNFR1 function in T cell–mediated hepatitis. (A) Serum ALT levels and (B) H&E liver
stainings with quantiﬁcation of damaged liver area of mice with indicated genotypes 8 hours after challenge (n 5 15, 17, 5, and 5,
respectively). (D) Serum ALT levels and designated serum cytokine concentrations of TNFR1MDC-KO and TNFR1FL mice 0-8 hours
after ConA injection (n 5 2-8 per time point). (E,F) Serum concentrations of chemokines after injection of ConA as measured by
enzyme-linked immunosorbent assay and quantitative polymerase chain reaction. *P < 0.05, **P < 0.01, ***P < 0.001, and ¶P > 0.18.
Graphs show mean and SEM. In photographs, * indicates central vein, bars 5 50 lm, and dashed line surrounds damaged area.
Abbreviation: INF, interferon
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MDCs. When we challenged the respective tissue-
speciﬁc knockout mice with listeria, we found that
mice with an LPC-selective ablation of TNFR1 were
protected, while mice with MDC-speciﬁc deletion of
TNFR1 succumbed to listeria similarly to the
TNFR12/2 mice (Fig. 7A). Given this important role
of MDCs as the target for TNF in combatting listeria
infection we asked whether TNFR1 in MDCs would
also be critical in endotoxic shock induced by LPS
injection. Interestingly, TNFR1MDC-KO mice were as
sensitive as control mice upon injection of a median
lethal dose of LPS (Fig. 7B). Moreover, upon injection
of LPS (median lethal dose) neither LPC, T-cell, nor
endothelial cell TNFR1 played a critical role as indi-
cated by the statistically insigniﬁcant differences in the
survival of the respective mice and their controls (Fig.
7C-E).
Taken together, these data show that, apart from its
detrimental function in T cell–mediated hepatitis,
MDC TNFR1 fulﬁlled a protective function in bacte-
rial infection, although TNFR1 in neither of the
examined cell types was critical to altering overall sur-
vival in endotoxic shock induced by LPS.
Discussion
It has been reported that TNF signaling is required
for hepatocyte cell death in mouse models of hepatitis.
Our results conﬁrm the essential function of TNFR1.
When using mouse lines with complete gene knock-
out, the complex crosstalk of immune cells and the
liver parenchyma is difﬁcult to interpret; however, by
using mice with conditional gene knockout, immune
cells have been identiﬁed as the source of TNF in
ConA-induced and LPS/Gal-induced hepatitis.(16,17)
Yet, the target cell type for binding of TNF remained
unknown. That mice challenged with LPS after being
pretreated with Gal develop hepatocyte death and liver
failure, which is mediated by TNFR1 on LPCs, was
certainly the favored concept. However, an unexpected
ﬁnding of this study was that TNFR1 plays no major
role in LPCs but instead does play a role in MDCs in
T cell–mediated, ConA-induced hepatitis. These data
do not conﬂict with ﬁndings that hematopoietic cells
release TNF in a c-Jun NH2-terminal kinase 1/2–
dependent manner in ConA-induced hepatitis.(17)
Instead, the fact that we failed to detect changes in
serum levels of TNF rather suggests that after ConA
injection, TNF is initially released from MDCs and
other immune cells and subsequently binds to TNFR1
in the same or a different subset of MDCs. This inter-
pretation would be consistent with the recently sug-
gested concept of crosstalk between sentinel and helper
macrophages as the source and target of TNF in bacte-
rial infection, respectively.(6) Schiwon et al. demon-
strated a macrophage TNFR-dependent release of
CXCL2 that allowed entry of neutrophils into the
uroepithelium. However, in ConA-induced liver
injury, we could not detect differences either in the
serum concentration of CXCL2 or in the recruitment
of neutrophils into the liver, suggesting that a different
effector pathway mediates the deleterious function of
TNFR1 in this model of hepatitis.
Our ﬁndings further exclude a role of Fas and
TRAILR in LPCs in ConA-induced hepatitis. It is
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FIG. 6. Context dependency of cell-speciﬁc TNFR1 in experimental hepatitis. (A) Survival of TNFR1MDC-KO and TNFR1FL mice
after LPS/Gal (n 5 4 and 4, respectively) and (B) ConA/Gal injection (n 5 3 and 5, respectively). (C) Serum ALT levels of
TNFR1MDC-KO and TNFR1FL mice 5 hours after ConA/Gal injection (n 5 2-4, mean and SEM). (D) Survival of TNFR1LPC-KO
and control mice after ConA/Gal injection.
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certain that under speciﬁc conditions such as pretreat-
ment with Gal (this study) or in the absence of nuclear
factor jB,(3,4) liver parenchymal DR signaling deter-
mines liver injury. Nonetheless, liver parenchymal DRs
are not required in ConA-induced hepatitis with a
functional hepatocyte survival pathway. These ﬁndings
are of importance because they underline the signiﬁ-
cance of a cell death effector system that functions
independently of DR ligands such as oxidative stress
(Supporting Fig. S6A), perforin-induced cell death,(32)
or liver parenchymal necrosis triggered by disturbances
of the microcirculation.(29) Importantly, however, our
results on the DR TNFR1 also demonstrate that
within the context of an impaired survival pathway the
site of the essential TNF function is the liver paren-
chyma but not MDCs. Impairment of the survival
pathway (Gal pretreatment) sensitized mice toward
LPC-intrinsic TNFR1-mediated liver injury, in the
context of both ConA and LPS injection. In contrast,
ConA-induced, T cell–dependent hepatitis requires
MDC-intrinsic, but not LPC-intrinsic, TNFR1. Prin-
cipally, the site-speciﬁc role of TNFR1 in experimental
hepatitis is manifold, and the competence of hepato-
cytes to induce the prosurvival pathway is a critical
determinant. In the absence of nuclear factor jB or
pretreatment with Gal, TNF causes hepatocyte apo-
ptosis (positive for cleaved caspase-3; Supporting Fig.
S4; Fig. 8A). Importantly, the inability to activate the
survival pathway renders hepatocytes sensitive to TNF
also in the context of ConA challenge as demonstrated
by our results showing that TNFR1LPC-KO, but not
TNFR1MDC-KO, mice were protected after injection
of ConA/Gal. In contrast, in the context of a func-
tional prosurvival response, ConA-induced hepatitis
completely depends on TNFR1 in MDCs (Fig. 8B).
Interestingly, we found that this cell death is
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FIG. 7. Protective function of myeloid cell–derived TNFR1 in infection. (A) Survival of mice with MDC-speciﬁc deletion of
TNFR1 and control mice after infection with Listeria monocytogenes. TNFR1d knockout allele for TNFR1 (see also Materials and
Methods). Survival of (B) TNFR1MDC-KO (n 5 13 and 11, respectively), (C) TNFR1LPC-KO (n 5 5 and 10, respectively), (D)
TNFR1TC-KO (n 5 5 and 11, respectively), and (E) TNFR1EC-KO (n 5 11 and 11, respectively) and TNFRFL control mice after
LPS injection.
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independent of caspase-3 activation and that it could
be prevented by inhibition of oxidative stress and
necrostatin-1(33) (Supporting Fig. S4 and S6).
Our ﬁndings identify the critical role of MDC-
intrinsic TNFR1 in T cell–mediated hepatitis.
Remarkably, apart from this detrimental role, MDC-
speciﬁc TNFR1 also fulﬁlls a protective function in
bacterial infection, as indicated by our results showing
that TNFR1MDC-KO mice succumbed to listeria infec-
tion. These data suggest that the same cell type from
the compartment of MDCs could fulﬁll an ambivalent
function in autoimmune disease and infection. Alter-
natively, different populations of MDCs such as
neutrophil granulocytes and different subsets of macro-
phages could fulﬁll a distinct function. Further experi-
ments with ablation of genes from the TNF pathway
selectively within the subcompartments of the hemato-
poietic fraction are required to determine the exact
sites of release and binding of TNF in order to unravel
its opposing functions in disease.
Anti-TNF agents have become an enormous success
in the clinical management of chronic inﬂammatory
conditions such as rheumatoid arthritis or inﬂamma-
tory bowel disease, albeit anti-TNF treatment can pro-
voke serious infectious complications. Interestingly,
the anti-TNF antibody inﬂiximab has been established
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FIG. 8. Proposed concept for the cell–speciﬁc function of TNFR1 in different models of experimental hepatitis. (A) Essential func-
tion of hepatocyte-intrinsic TNFR1 in the context of an inhibited survival pathway. ¶Note that TNF could be induced through LPS
but also through other sources such as ConA (see Fig. 6). (B) Essential role of MDC-intrinsic, but not hepatocyte-intrinsic, TNFR1
in the context of a functional survival pathway in the T cell–dependent model of ConA-induced liver injury. Note that, as opposed to
(A), the effector phase of cell death induction in (B) is independent of liver parenchymal DRs and FADD. While cell-type speciﬁc
TNFR1 fulﬁlls deleterious functions in hepatitis TNFR1, in MDCs it has an additional protective function in the defense against bac-
teria such as in listeria infection (Fig. 5). Abbreviations: LSEC, liver sinusoidal endothelial cell; MyD88, myeloid differentiation pri-
mary response 88; NF-jB, nuclear factor jB; NKT, natural killer T; ROS, reactive oxygen species; TLR4, Toll-like receptor 4.
                                                                                                                                      
WROBLEWSKI, ARMAKA, ET AL. HEPATOLOGY, Month 2016
12
as a rescue therapy for patients with difﬁcult-to-treat
AIH when standard treatment is not tolerated or inef-
ﬁcient.(9) While anti-TNF is thought to neutralize
soluble and membrane-bound TNF and might also
trigger apoptosis of T cells in AIH,(9) the mechanism
of action is unrecognized and the role of MDCs has
not been addressed. Our ﬁndings in murine T cell–
induced hepatitis suggest that TNF could similarly act
upon MDCs resulting in T-cell activation in human
AIH. Of note, our data imply that the observed sus-
ceptibility to infections upon treatment with anti-TNF
agents could at least in part be explained by the func-
tion of TNFR1 on MDCs.
In conclusion, this study reveals that the essential
site of the detrimental function of TNFR1 is depend-
ent on the nature of hepatitis. Within the context of an
impaired survival pathway, liver injury critically
depends on hepatocyte-intrinsic TNFR1. MDC-
intrinsic, but not hepatocyte-intrinsic, TNFR1, in
contrast, is essential for T cell–mediated hepatitis.
Importantly, however, TNF also fulﬁlls an antibacterial
function through TNFR1 on MDCs. The results
describe a divergent role of MDC TNFR1 in autoim-
munity and infection.
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